fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ECCO 2018: Novel treatments in IBD

Written by | 11 Feb 2018

The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.

New insights into HL biology

Written by | 5 Feb 2018

Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.

Which groups benefited most from an ECHELON-1 approach?

Written by | 5 Feb 2018

Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.

ASH 2017 Highlights

Written by | 5 Feb 2018

Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.

ASH 2017: Mixed results for new NHL therapies

Written by | 19 Jan 2018

Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.

ASH 2017: ECHELON-1: Brentuximab vedotin plus AVD in HL produces PFS improvement

Written by | 19 Jan 2018

Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.

Hesitation still surrounds use of ‘cure’ word in MM

Written by | 15 Jan 2018

Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.

Mixed results for new NHL therapies

Written by | 15 Jan 2018

Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.

ICML 2017: Response-adapted therapy for Hodgkin’s lymphoma

Written by | 30 Sep 2017

Professor Peter Johnson (Southampton, UK) tells us what’s new with response-adapted therapy and what are the benefits to patients.

ICML Highlights: Hot debates in Hodgkin Lymphoma

Written by | 9 Aug 2017

An entertaining case discussion session, chaired by Craig Moskowitz at ICML-14, highlighted some of the hot debates in Hodgkin lymphoma as discussed here by Professor Stephen Ansell (Rochester, USA),… read more.

ICML 2017: Highlights

Written by | 30 Jul 2017

Interviewer: Esther Drain Dr Toby Eyre (Oxford),  Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell therapy and the first EZH2 inhibitor, tazemetostat, in… read more.

ICML 2017: The role of stem cell transplantation for lymphoma in 2017

Written by | 11 Jul 2017

By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.